Stockreport

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF - Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Pat [Read more]